BRD4 and cancer: A screening assay of 628 kinase inhibitors to determine activity against the first bromodomain of BRD4, which is overexpressed in many cancers [52], showed fedratinib was among nine kinase inhibitor drugs to exert potent bromodomain inhibition with nanomolar activity (IC50 value 164 ± 10 nM) at therapeutically relevant concentrations [45].